Foamix Inc., of Rehovot, Israel, said it established a U.S. subsidiary, Foamix Pharmaceuticals Inc., located in Bridgewater, N.J., to conduct clinical development operations, including planned trials of minocycline foam, that can be used for the treatment of acne, skin infections and rosacea, and to manage regulatory affairs and to build commercial infrastructure.